Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: A meta-analysis

British Journal of Radiology

Volumn 78, Issue 933, 2005, Pages 777-782

  Dayes, Ian S ^a,b   Abuzallouf, S ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Department of Radiation Oncology   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

MISONIDAZOLE; NITROIMIDAZOLE; ORNIDAZOLE; PIMONIDAZOLE;

ADULT; AGED; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; MEDLINE; META ANALYSIS; NEUROPATHY; QUALITY CONTROL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NITROIMIDAZOLES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 24344486882     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/57750595     Document Type: Review

References (17)

1. Adams GE, Dische S, Fowler JF, Thomlinson RH. Hypoxic cell sensitisers in radiotherapy. Lancet 1976;1:186-8.
2. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 1994;6: 509-18.
3. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
4. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 1998;352:609-13.
5. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992;45:255-65.
6. Green J, Kirwan J, Tierney J, Symonds P, Fresco L, Williams C, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix (Cochrane Review). Cochrane Database Syst Rev 2001;4:CD002225.
7. Fleiss JL. The statistical basis of meta-analysis. Stat Meth Med Res 1993;2:121-45.
8. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000;53:207-16.
9. Colton T. Statistics in medicine. Boston: Little, Brown and Co, 1974.
10. Dische S, Adams GE, Ash DV, Baker J, Barley V, Bleehen NM, et al. The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. (A report from the MRC Working Party on Misonidazole for Cancer of the Cervix.) Br J Radiol 1984;57:491-9.
11. Dische S, Chassagne D, Hope-Stone HF, Dawes P, Roberts J, Yosef H, et al. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993;26:93-103.
12. Leibel S, Bauer M, Wasserman T, Marcial V, Rotman M, Hornback N, et al. Radiotherapy with or without misonidazole for patients withstage IIIb or stage IVa squamous cell carcinoma of the uterine cervix: preliminary report of a Radiation Therapy Oncology Group randomized trial. Int J Radiat Oncol Biol Phys 1987;13:541-9.
13. Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J, et al. Irradiation with or without misonidazole for patients with stages IIIb and IVa carcinoma of the cervix: Final results of RTOG 80-05. Int J Radiat Oncol Biol Phys 1999;44:513-7.
14. Okkan S, Atkovar G, Sahinler I, Turkan S, Uzel R. A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long-term results. Br J Cancer 1996;74 (Suppl. 27):S282-6.
15. Overgaard J, Bentzen SM, Kolstad P, Kjoerstad K, Davy M, Bertelsen K, et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1989;16:1069-72.
16. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthalsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
17. Timothy AR, Overgaard J, Overgaard M. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 1984;10:1765-8.